Keryx Biopharmaceuticals Inc. (KERX) PT Set at $7.00 by FBR & Co
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) has been assigned a $7.00 price target by stock analysts at FBR & Co in a report released on Friday. The firm presently has a a “hold” rating on the biopharmaceutical company’s stock. FBR & Co’s target price indicates a potential upside of 11.29% from the company’s previous close.
Several other analysts also recently issued reports on KERX. Maxim Group downgraded Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 1st. Stifel Nicolaus downgraded Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 2nd. Brean Capital downgraded Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 2nd. Ladenburg Thalmann upped their target price on Keryx Biopharmaceuticals from $9.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, August 2nd. Finally, Raymond James Financial Inc. upped their target price on Keryx Biopharmaceuticals from $7.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, August 2nd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. Keryx Biopharmaceuticals presently has an average rating of “Hold” and a consensus price target of $8.28.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) opened at 6.29 on Friday. The stock’s 50 day moving average is $5.02 and its 200-day moving average is $5.45. Keryx Biopharmaceuticals has a 1-year low of $2.80 and a 1-year high of $7.80. The stock’s market cap is $666.49 million.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by $0.19. The company had revenue of $6.30 million for the quarter, compared to analyst estimates of $5.53 million. Keryx Biopharmaceuticals had a negative return on equity of 270.26% and a negative net margin of 584.76%. Keryx Biopharmaceuticals’s quarterly revenue was up 50.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.29) EPS. On average, analysts anticipate that Keryx Biopharmaceuticals will post ($1.41) EPS for the current year.
Large investors have recently made changes to their positions in the company. Alpine Partners VI LLC bought a new stake in shares of Keryx Biopharmaceuticals during the second quarter worth about $110,000. Trexquant Investment LP acquired a new stake in Keryx Biopharmaceuticals during the second quarter valued at $115,000. Cambridge Investment Research Advisors Inc. boosted its stake in Keryx Biopharmaceuticals by 38.2% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 18,100 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 5,000 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Keryx Biopharmaceuticals during the third quarter valued at $121,000. Finally, LMR Partners LLP acquired a new stake in Keryx Biopharmaceuticals during the second quarter valued at $125,000. 62.28% of the stock is owned by hedge funds and other institutional investors.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.
Receive News & Stock Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related stocks with our FREE daily email newsletter.